| 1. |
Franco AMM, Medina FMC, Balbi GGM, et al. Ophthalmologic manifestations in primary antiphospholipid syndrome patients: a cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature[J]. Lupus, 2020, 29(12): 1528-1543. DOI: 10.1177/0961203320949667.
|
| 2. |
Bick RL, Baker WF Jr. Antiphospholipid thrombosis syndromes[J]. Hematol Oncol Clin North Am, 2003, 17(1): 115-147. DOI: 10.1016/j.hoc.2007.11.003.
|
| 3. |
Trentin F, Zucchi D, Signorini V, et al. One year in review 2021: systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2021, 39(2): 231-241. DOI: 10.55563/clinexprheumatol/7gzsxp.
|
| 4. |
Cavazzana I, Andreoli L, Limper M, et al. Update on antiphospholipid syndrome: ten topics in 2017[J/OL]. Curr Rheumatol Rep, 2018, 20(3): 15[2018-03-15]. https://pubmed.ncbi.nlm.nih.gov/29541874/. DOI: 10.1007/s11926-018-0718-4.
|
| 5. |
Aldhefeery N, Alhadhood N, Alkadi A. Bilateral retinal vasculitis as initial presentation of systemic lupus erythematosus with secondary antiphospholipid syndrome[J/OL]. Am J Case Rep, 2023, 24: e942085[2023-11-28]. https://pubmed.ncbi.nlm.nih.gov/38013402/. DOI: 10.12659/AJCR.942085.
|
| 6. |
Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, et al. Systematic review of case reports of antiphospholipid syndrome following infection[J]. Lupus, 2016, 25(14): 1520-1531. DOI: 10.1177/0961203316640912.
|
| 7. |
Knight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome[J]. Semin Immunopathol, 2022, 44(3): 347-362. DOI: 10.1007/s00281-022-00916-w.
|
| 8. |
Salter BM, Crowther MA. Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease[J]. Hematology Am Soc Hematol Educ Program, 2024, 2024(1): 214-221. DOI: 10.1182/hematology.2024000544.
|
| 9. |
Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features[J]. Autoimmun Rev, 2015, 14(5): 401-414. DOI: 10.1016/j.autrev.2015.01.002.
|
| 10. |
Schreiber K, Sciascia S, de Groot PG. et al. Antiphospholipid syndrome[J/OL]. Nat Rev Dis Primer, 2018, 4: 17103[2018-01-11]. https://pubmed.ncbi.nlm.nih.gov/29321641/. DOI: 10.1038/nrdp.2017.103.
|
| 11. |
Gaspar P, Sciascia S, Tektonidou MG. Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations[J]. Rheumatology (Oxford), 2024, 63(SI): 24-36. DOI: 10.1093/rheumatology/kead571.
|
| 12. |
Erkan D. Expert perspective: management of microvascular and catastrophic antiphospholipid syndrome[J]. Arthritis Rheumatol, 2021, 73(10): 1780-1790. DOI: 10.1002/art.41891.
|
| 13. |
Dufrost V, Risse J, Reshetnyak T, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. results from an international patient-level data meta-analysis[J]. Autoimmun Rev, 2018, 17: 1011-1021. DOI: 10.1016/j.autrev.2018.04.009.
|
| 14. |
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome[J]. N Engl J Med, 2018, 378(21): 2010-2021. DOI: 10.1056/NEJMra1705454.
|
| 15. |
Yang HK, Moon KW, Ji MJ, et al. Primary antiphospholipid syndrome presenting with homonymous quadrantanopsia[J]. Am J Ophthalmol Case Rep, 2018, 10: 208-210. DOI: 10.1016/j.ajoc.2018.03.001.
|
